Loading…
Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis
In this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC). We comprehensively searched electronic databases, including PubMed and Embase, from inception through...
Saved in:
| Published in: | Cancer management and research 2019-01, Vol.11, p.1907-1920 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c588t-6e582c20ebb719d7a5a593172c58f8876c28d59743e615e81d8ef7168e4326c43 |
|---|---|
| cites | |
| container_end_page | 1920 |
| container_issue | |
| container_start_page | 1907 |
| container_title | Cancer management and research |
| container_volume | 11 |
| creator | Gao, Xu-Ping Liu, Yan-Hua Liu, Ze-Ying Wang, Li-Jun Jing, Chun-Xia Zhu, Sui Zeng, Fang-Fang |
| description | In this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC).
We comprehensively searched electronic databases, including PubMed and Embase, from inception through October 2018. A random-effects model was used to calculate pooled HRs and their 95% CIs for overall survival (OS) and progression-free survival (PFS). The low LMR group was treated as the reference group.
Twelve studies, including 3,346 OC cases at baseline, were included. Overall, our results indicated that LMR was positively associated with both OS (HR: 1.85, 95% CI: 1.50-2.28, |
| doi_str_mv | 10.2147/CMAR.S184970 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2aa9f9f4841b47b59932712779d330d2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A681326053</galeid><doaj_id>oai_doaj_org_article_2aa9f9f4841b47b59932712779d330d2</doaj_id><sourcerecordid>A681326053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c588t-6e582c20ebb719d7a5a593172c58f8876c28d59743e615e81d8ef7168e4326c43</originalsourceid><addsrcrecordid>eNptksuP0zAQxiMEYpeFG2dkiQsHUuJHYpsDUlXxWGkRiMfZmjqT1lUSd2230P8ed1tWLUI-eDTzm8-a8VcUz2k1YVTIN7PP02-T71QJLasHxSWlUpeUM_bwJL4onsS4qqpGUy4eFxe8Uorm6mXx-2vAFBDSgGMi_W5YL73dJSyTLwc_3sUkQHKeQCRA1gFbZ5MPxHckbsLWbaEnkNEFWWcsq0Tyy6Ul8VsIDkZiYbQY3ubeAROUMEK_iy4-LR510Ed8dryvip8f3v-YfSpvvny8nk1vSlsrlcoGa8Usq3A-l1S3EmqoNaeS5XKnlGwsU22tpeDY0BoVbRV2kjYKBWeNFfyquD7oth5WZh3cAGFnPDhzl_BhYSAkZ3s0DEB3uhNK0LmQ81prziRlUuqW86plWevdQWu9mQ_Y2jxsgP5M9LwyuqVZ-K1puFaiolng1VEg-NsNxmQGFy32PYzoN9EwqnnDaE1VRl_-g678JuTlZYoxIbjS-oRaQB7AjZ3P79q9qJk2Kn99U9U8U5P_UPm0ODjrR-xczp81vD402OBjDNjdz0grs3ed2bvOHF2X8Rene7mH_9qM_wHmoNGP</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2224438998</pqid></control><display><type>article</type><title>Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis</title><source>Taylor & Francis Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Gao, Xu-Ping ; Liu, Yan-Hua ; Liu, Ze-Ying ; Wang, Li-Jun ; Jing, Chun-Xia ; Zhu, Sui ; Zeng, Fang-Fang</creator><creatorcontrib>Gao, Xu-Ping ; Liu, Yan-Hua ; Liu, Ze-Ying ; Wang, Li-Jun ; Jing, Chun-Xia ; Zhu, Sui ; Zeng, Fang-Fang</creatorcontrib><description>In this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC).
We comprehensively searched electronic databases, including PubMed and Embase, from inception through October 2018. A random-effects model was used to calculate pooled HRs and their 95% CIs for overall survival (OS) and progression-free survival (PFS). The low LMR group was treated as the reference group.
Twelve studies, including 3,346 OC cases at baseline, were included. Overall, our results indicated that LMR was positively associated with both OS (HR: 1.85, 95% CI: 1.50-2.28,
<0.001;
=76.5%) and PFS (HR: 1.70, 95% CI: 1.49-1.94,
<0.001;
=24.4%) among OC patients. Stratified analyses indicated that, for OS, the LMR's protective effect was more evident in studies conducted among younger patients (<55 years) than in those conducted among older patients (≥55 years;
for interaction =0.017), which was confirmed by meta-regression analysis (
=0.004).
This study suggested that a higher pretreatment LMR level was associated with a favorable prognosis among OC patients. Future large-scale prospective clinical trials are needed to confirm the prognostic value of LMR among OC patients.</description><identifier>ISSN: 1179-1322</identifier><identifier>EISSN: 1179-1322</identifier><identifier>DOI: 10.2147/CMAR.S184970</identifier><identifier>PMID: 30881117</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Age ; Analysis ; Breast cancer ; Cancer patients ; Cell adhesion & migration ; Inflammation ; Lung cancer ; Lymphocyte-to-monocyte ratio ; Lymphocytes ; Medical prognosis ; Medical research ; Medicine ; Medicine, Experimental ; Meta-analysis ; Original Research ; Ovarian cancer ; Patient outcomes ; Patients ; Prognosis ; Quality ; Software ; Studies ; Survival analysis</subject><ispartof>Cancer management and research, 2019-01, Vol.11, p.1907-1920</ispartof><rights>COPYRIGHT 2019 Dove Medical Press Limited</rights><rights>2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Gao et al. This work is published and licensed by Dove Medical Press Limited 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c588t-6e582c20ebb719d7a5a593172c58f8876c28d59743e615e81d8ef7168e4326c43</citedby><orcidid>0000-0001-6197-2303 ; 0000-0003-3813-2036</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2224438998/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2224438998?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30881117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Xu-Ping</creatorcontrib><creatorcontrib>Liu, Yan-Hua</creatorcontrib><creatorcontrib>Liu, Ze-Ying</creatorcontrib><creatorcontrib>Wang, Li-Jun</creatorcontrib><creatorcontrib>Jing, Chun-Xia</creatorcontrib><creatorcontrib>Zhu, Sui</creatorcontrib><creatorcontrib>Zeng, Fang-Fang</creatorcontrib><title>Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis</title><title>Cancer management and research</title><addtitle>Cancer Manag Res</addtitle><description>In this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC).
We comprehensively searched electronic databases, including PubMed and Embase, from inception through October 2018. A random-effects model was used to calculate pooled HRs and their 95% CIs for overall survival (OS) and progression-free survival (PFS). The low LMR group was treated as the reference group.
Twelve studies, including 3,346 OC cases at baseline, were included. Overall, our results indicated that LMR was positively associated with both OS (HR: 1.85, 95% CI: 1.50-2.28,
<0.001;
=76.5%) and PFS (HR: 1.70, 95% CI: 1.49-1.94,
<0.001;
=24.4%) among OC patients. Stratified analyses indicated that, for OS, the LMR's protective effect was more evident in studies conducted among younger patients (<55 years) than in those conducted among older patients (≥55 years;
for interaction =0.017), which was confirmed by meta-regression analysis (
=0.004).
This study suggested that a higher pretreatment LMR level was associated with a favorable prognosis among OC patients. Future large-scale prospective clinical trials are needed to confirm the prognostic value of LMR among OC patients.</description><subject>Age</subject><subject>Analysis</subject><subject>Breast cancer</subject><subject>Cancer patients</subject><subject>Cell adhesion & migration</subject><subject>Inflammation</subject><subject>Lung cancer</subject><subject>Lymphocyte-to-monocyte ratio</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine, Experimental</subject><subject>Meta-analysis</subject><subject>Original Research</subject><subject>Ovarian cancer</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Quality</subject><subject>Software</subject><subject>Studies</subject><subject>Survival analysis</subject><issn>1179-1322</issn><issn>1179-1322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptksuP0zAQxiMEYpeFG2dkiQsHUuJHYpsDUlXxWGkRiMfZmjqT1lUSd2230P8ed1tWLUI-eDTzm8-a8VcUz2k1YVTIN7PP02-T71QJLasHxSWlUpeUM_bwJL4onsS4qqpGUy4eFxe8Uorm6mXx-2vAFBDSgGMi_W5YL73dJSyTLwc_3sUkQHKeQCRA1gFbZ5MPxHckbsLWbaEnkNEFWWcsq0Tyy6Ul8VsIDkZiYbQY3ubeAROUMEK_iy4-LR510Ed8dryvip8f3v-YfSpvvny8nk1vSlsrlcoGa8Usq3A-l1S3EmqoNaeS5XKnlGwsU22tpeDY0BoVbRV2kjYKBWeNFfyquD7oth5WZh3cAGFnPDhzl_BhYSAkZ3s0DEB3uhNK0LmQ81prziRlUuqW86plWevdQWu9mQ_Y2jxsgP5M9LwyuqVZ-K1puFaiolng1VEg-NsNxmQGFy32PYzoN9EwqnnDaE1VRl_-g678JuTlZYoxIbjS-oRaQB7AjZ3P79q9qJk2Kn99U9U8U5P_UPm0ODjrR-xczp81vD402OBjDNjdz0grs3ed2bvOHF2X8Rene7mH_9qM_wHmoNGP</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Gao, Xu-Ping</creator><creator>Liu, Yan-Hua</creator><creator>Liu, Ze-Ying</creator><creator>Wang, Li-Jun</creator><creator>Jing, Chun-Xia</creator><creator>Zhu, Sui</creator><creator>Zeng, Fang-Fang</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6197-2303</orcidid><orcidid>https://orcid.org/0000-0003-3813-2036</orcidid></search><sort><creationdate>20190101</creationdate><title>Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis</title><author>Gao, Xu-Ping ; Liu, Yan-Hua ; Liu, Ze-Ying ; Wang, Li-Jun ; Jing, Chun-Xia ; Zhu, Sui ; Zeng, Fang-Fang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c588t-6e582c20ebb719d7a5a593172c58f8876c28d59743e615e81d8ef7168e4326c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age</topic><topic>Analysis</topic><topic>Breast cancer</topic><topic>Cancer patients</topic><topic>Cell adhesion & migration</topic><topic>Inflammation</topic><topic>Lung cancer</topic><topic>Lymphocyte-to-monocyte ratio</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine, Experimental</topic><topic>Meta-analysis</topic><topic>Original Research</topic><topic>Ovarian cancer</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Quality</topic><topic>Software</topic><topic>Studies</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Xu-Ping</creatorcontrib><creatorcontrib>Liu, Yan-Hua</creatorcontrib><creatorcontrib>Liu, Ze-Ying</creatorcontrib><creatorcontrib>Wang, Li-Jun</creatorcontrib><creatorcontrib>Jing, Chun-Xia</creatorcontrib><creatorcontrib>Zhu, Sui</creatorcontrib><creatorcontrib>Zeng, Fang-Fang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer management and research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Xu-Ping</au><au>Liu, Yan-Hua</au><au>Liu, Ze-Ying</au><au>Wang, Li-Jun</au><au>Jing, Chun-Xia</au><au>Zhu, Sui</au><au>Zeng, Fang-Fang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis</atitle><jtitle>Cancer management and research</jtitle><addtitle>Cancer Manag Res</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>11</volume><spage>1907</spage><epage>1920</epage><pages>1907-1920</pages><issn>1179-1322</issn><eissn>1179-1322</eissn><abstract>In this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC).
We comprehensively searched electronic databases, including PubMed and Embase, from inception through October 2018. A random-effects model was used to calculate pooled HRs and their 95% CIs for overall survival (OS) and progression-free survival (PFS). The low LMR group was treated as the reference group.
Twelve studies, including 3,346 OC cases at baseline, were included. Overall, our results indicated that LMR was positively associated with both OS (HR: 1.85, 95% CI: 1.50-2.28,
<0.001;
=76.5%) and PFS (HR: 1.70, 95% CI: 1.49-1.94,
<0.001;
=24.4%) among OC patients. Stratified analyses indicated that, for OS, the LMR's protective effect was more evident in studies conducted among younger patients (<55 years) than in those conducted among older patients (≥55 years;
for interaction =0.017), which was confirmed by meta-regression analysis (
=0.004).
This study suggested that a higher pretreatment LMR level was associated with a favorable prognosis among OC patients. Future large-scale prospective clinical trials are needed to confirm the prognostic value of LMR among OC patients.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>30881117</pmid><doi>10.2147/CMAR.S184970</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-6197-2303</orcidid><orcidid>https://orcid.org/0000-0003-3813-2036</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-1322 |
| ispartof | Cancer management and research, 2019-01, Vol.11, p.1907-1920 |
| issn | 1179-1322 1179-1322 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_2aa9f9f4841b47b59932712779d330d2 |
| source | Taylor & Francis Open Access; Publicly Available Content Database; PubMed Central |
| subjects | Age Analysis Breast cancer Cancer patients Cell adhesion & migration Inflammation Lung cancer Lymphocyte-to-monocyte ratio Lymphocytes Medical prognosis Medical research Medicine Medicine, Experimental Meta-analysis Original Research Ovarian cancer Patient outcomes Patients Prognosis Quality Software Studies Survival analysis |
| title | Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A15%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20lymphocyte-to-monocyte%20ratio%20as%20a%20predictor%20of%20survival%20among%20patients%20with%20ovarian%20cancer:%20a%20meta-analysis&rft.jtitle=Cancer%20management%20and%20research&rft.au=Gao,%20Xu-Ping&rft.date=2019-01-01&rft.volume=11&rft.spage=1907&rft.epage=1920&rft.pages=1907-1920&rft.issn=1179-1322&rft.eissn=1179-1322&rft_id=info:doi/10.2147/CMAR.S184970&rft_dat=%3Cgale_doaj_%3EA681326053%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c588t-6e582c20ebb719d7a5a593172c58f8876c28d59743e615e81d8ef7168e4326c43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2224438998&rft_id=info:pmid/30881117&rft_galeid=A681326053&rfr_iscdi=true |